Biotech VaxGen ( VXGN) is adding to its huge September run-up as shares rise on word it was awarded an $80 million government contract for an anthrax vaccine.

In recent trading, shares were up 87 cents, or 7.2%, to $12.94.

The company said the three-year National Institute of Allergy and Infectious Diseases contract will pay for up to 3 million doses of the vaccine, which will be tested on animals.

Shares of VaxGen have nearly tripled over the past month, rising from a close of $4.32 on Sept. 2. While its AIDS vaccine results bombed earlier this year, investors have become excited over the company's promise in developing reliable anthrax and smallpox vaccines.

Those vaccines have a good shot at attracting a chunk of the $6 billion the government will spend in the next 10 years on the so-called Project BioShield, a program to protect Americans from bioterrorism.

More from Opinion

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

Many Chip Stocks Look Cheap Here, as Long as the Economy Holds Up

Many Chip Stocks Look Cheap Here, as Long as the Economy Holds Up

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense